CLDN18 and neoplasm: The lead molecule, anti-CLDN18.2 hu7v3-Fc, demonstrated enhanced in vitro and in vivo anti-tumor activities, compared to the benchmark Zolbetuximab in CLDN18.2-positive gastric and pancreatic tumor cells.